RMS Medical Products Receives Favorable Court Ruling

Download as PDF

CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical” or “the Company”) today announced that on June 24, 2019 the United States District Court for the Eastern District of Texas (Case No. 2:15-CV-01167-JRG-RSP) issued a decision recommending that RMS Medical’s motion for summary judgement of non-infringement against EMED Technologies (“EMED”) be granted and that the case before it be dismissed.

As previously reported, on June 25, 2015 EMED filed a case in the United States District Court for the Eastern District of Texas claiming patent infringement on one of its patents by the Company’s needle sets and seeking unspecified monetary damages. This case is one of several pending between RMS Medical and EMED.

On June 26, 2019, EMED filed objections to the decision.

The decision of the Magistrate Judge serving in the United States District Court for the Eastern District of Texas, EMED’s objections and associated documents will be reviewed by the District Judge. RMS Medical believes it will prevail on the merits and the District Judge will uphold the decision of the Magistrate Judge and dismiss the case, although there can be no assurances.

About RMS Medical Products

RMS Medical develops, manufactures and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information about RMS Medical, please visit www.rmsmedicalproducts.com.

Forward-Looking Statements

The statements contained herein include prospects, statements of future expectations and other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management's current views and assumptions and involve known and unknown risks and uncertainties, identified by words such as "believes." Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Factors that may cause actual results to differ materially from current expectations and other risks are discussed in RMS Medical’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, which filings are available from the SEC and RMS Medical’s website. RMS Medical undertakes no obligation to update any forward-looking statements.

The Equity Group Inc.
Devin Sullivan
Senior Vice President
212-836-9608
dsullivan@equityny.com

Kalle Ahl, CFA
Vice President
212-836-9614
kahl@equityny.com

Source: RMS Medical Products

Released June 27, 2019